Interim report January

Continuing good performance
Second quarter:

Continuing operations

  · Sales growth was 29 percent in local currency. Sales amounted to SEK 116
(95) million, corresponding to an increase of 22 percent in SEK.
  · Operating income (EBIT) amounted to SEK 19 (13) million, corresponding to an
operating margin of 16 (13) percent.
  · The comparative figures for 2012 relate to continuing operations, fertility,
unless otherwise stated.
  · Net income amounted to SEK 12 (11) million, which gave earnings per share of
SEK 0.62 (0.54).
  · Dividend of SEK 0.60 (0.60) per share, in total SEK 11,898,562 (11,737,661).
  · On April 1, 2013 Vitrolife exercised an option to acquire all the shares in
HertArt ApS.

First half year:

Continuing operations

  · Sales growth was 28 percent in local currency. Sales amounted to SEK 221
(181) million, corresponding to an increase of 22 percent in SEK.
  · Operating income (EBIT) amounted to SEK 36 (23) million, corresponding to an
operating margin of 16 (13) percent.
  · The comparative figures for 2012 relate to continuing operations, fertility,
unless otherwise stated.
  · Net income amounted to SEK 24 (18) million, which gave earnings per share of
SEK 1.22 (0.92).

Gothenburg, July 12, 2013

VITROLIFE AB (publ)

Thomas Axelsson, CEO
Queries should be addressed to:

Thomas Axelsson, CEO, tel 46 31 721 80 01

Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on July
12, 2013 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife (http://www.vitrolife.com/en/Corporate/) is an international medical
device Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/)
product area develops, produces and markets medical devices for assisted
reproduction. Work is also carried out to enable the use and handling of stem
cells for therapeutic purposes.

Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 230
employees and the company's products are sold in almost 110 markets. The company
is headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The
Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is
listed on NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Small Cap.

________________________________________________________________________________
_ 
________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/
Interim report January – June 2013

Attachments
